BBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. BridgeBio Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $1.238. BridgeBio Pharma's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2025-03-30), BridgeBio Pharma's share price is $35.11. BridgeBio Pharma's Median PS Value is $0.00. Therefore, BridgeBio Pharma's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for BridgeBio Pharma's Median PS Value or its related term are showing as below:
The historical data trend for BridgeBio Pharma's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma Annual Data | |||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
BridgeBio Pharma Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Median PS Value | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, BridgeBio Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Price-to-Median-PS-Value falls into.
BridgeBio Pharma's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 1.238 | * | 0 | |
= | 0.00 |
10-Year Median PS Ratio is 0.
BridgeBio Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.238.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (NAS:BBIO) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
BridgeBio Pharma's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 35.11 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of BridgeBio Pharma's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Hannah Valantine | director | 1305 O'BRIEN DRIVE, MENLO PARK CA 94025 |
Kkr Genetic Disorder L.p. | 10 percent owner | C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019 |
Neil Kumar | director, officer: See Remarks | C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304 |
Brian C Stephenson | officer: See Remarks | 3160 PORTER DR, STE 250, PALO ALTO CA 94304 |
Viking Global Investors Lp | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Randal W Scott | director | 171 MAIN STREET #225, LOS ALTOS CA 94022 |
Frank Mccormick | officer: Chairman of Oncology | C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001 |
Viking Global Opportunities Parent Gp Llc | 10 percent owner | 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901 |
Douglas A. Dachille | director | 175 WATER STREET, NEW YORK NY 10038 |
Andrew Lo | director | C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142 |
Ronald J Daniels | director | C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901 |
Fred Hassan | director | C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487 |
James C Momtazee | director | 2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025 |
Brent L Saunders | director | 2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033 |
Andrea Ellis | director | C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301 |
From GuruFocus
By Marketwired • 02-13-2025
By GlobeNewswire • 11-23-2024
By Marketwired • 02-20-2025
By Marketwired • 02-11-2025
By Marketwired • 11-23-2024
By Marketwired • 10-24-2024
By GuruFocus News • 02-20-2025
By GlobeNewswire • 11-18-2024
By GuruFocus News • 11-21-2024
By Marketwired • 02-26-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.